Free Trial
Ends Tomorrow! Last Chance to Get MarketBeat All Access at $149
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149
Claim MarketBeat All Access Sale Promotion

Stryker (SYK) Stock Forecast & Price Target

Stryker logo
$308.35 +4.35 (+1.43%)
As of 10:02 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Stryker - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
6
Buy
18

Based on 24 Wall Street analysts who have issued ratings for Stryker in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 6 have given a hold rating, 17 have given a buy rating, and 1 has given a strong buy rating for SYK.

Consensus Price Target

$369.00
19.67% Upside
According to the 24 analysts' twelve-month price targets for Stryker, the average price target is $369.00. The highest price target for SYK is $465.00, while the lowest price target for SYK is $298.00. The average price target represents a forecasted upside of 19.67% from the current price of $308.35.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for SYK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Stryker and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SYK Analyst Ratings Over Time

TypeCurrent Forecast
10/29/25 to 10/29/26
1 Month Ago
9/29/25 to 9/29/26
3 Months Ago
7/31/25 to 7/31/26
1 Year Ago
10/29/24 to 10/29/25
Strong Buy
1 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
17 Buy rating(s)
18 Buy rating(s)
17 Buy rating(s)
15 Buy rating(s)
Hold
6 Hold rating(s)
5 Hold rating(s)
5 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$369.00$374.42$391.09$432.85
Forecasted Upside19.67% Upside34.07% Upside19.82% Upside17.25% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

SYK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SYK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Stryker Stock vs. The Competition

TypeStrykerHealthcare CompaniesBroader Market
Consensus Rating Score
2.79
2.32
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside21.44% Upside106.19% Upside16.60% Upside
News Sentiment Rating
Positive News

See Recent SYK News
Positive News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/12/2026
BTIG Research logo
BTIG Research
3 of 5 stars
Ryan Zimmerman
Ryan Zimmerman
3 of 5 stars
Lower TargetBuy$358.00 ➝ $316.00+13.97%
10/7/2026 Reiterated RatingMarket Perform
10/7/2026
Barclays PLC logo
Barclays
3 of 5 stars
UpgradeStrong-Buy
10/6/2026Lower TargetHold$340.00 ➝ $310.00+11.01%
9/30/2026Lower TargetBuy$360.00 ➝ $330.00+18.17%
9/22/2026Lower TargetHold$355.00 ➝ $298.00+8.88%
9/18/2026Lower TargetBuy$400.00 ➝ $385.00+37.32%
9/10/2026Lower TargetBuy$399.00 ➝ $360.00+31.42%
9/9/2026 Reiterated RatingOutperform$317.00+14.21%
9/9/2026Lower TargetOverweight$418.00 ➝ $348.00+26.02%
8/13/2026DowngradeOutperform ➝ Peer Perform
8/3/2026Lower TargetMarket Outperform$440.00 ➝ $400.00+19.13%
7/31/2026 Reiterated RatingHold (C)
7/31/2026Lower TargetOutperform$435.00 ➝ $420.00+30.93%
7/31/2026 Set Target$370.00+15.35%
7/31/2026Lower TargetOverweight$420.00 ➝ $390.00+11.95%
7/31/2026Lower TargetOverweight$400.00 ➝ $350.00+7.71%
7/28/2026Initiated CoverageBuy$400.00+18.58%
7/9/2026 Set Target$370.00+12.96%
7/6/2026 Set Target$350.00+8.72%
6/5/2026Lower TargetOutperform$410.00 ➝ $407.00+35.30%
5/1/2026Reiterated RatingNeutral$361.00+22.19%
5/1/2026 Set Target$385.00+27.40%
5/1/2026 Set Target$315.00+1.65%
5/1/2026Lower TargetBuy$454.00 ➝ $418.00+32.85%
3/5/2026 Reiterated RatingOutperform
3/4/2026Reiterated RatingBuy$465.00+21.57%
9/18/2025 Set Target$420.00+11.54%
5/2/2025Boost TargetBuy$405.00 ➝ $456.00+20.75%
12/2/2024 UpgradeEqual Weight ➝ Overweight$370.00 ➝ $445.00+13.48%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 10:02 AM ET.


Should I Buy Stryker Stock? SYK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, October 28, 2026. Please send any questions or comments about these Stryker pros and cons to contact@marketbeat.com.

Stryker
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Stryker Co.:

  • Stryker Co. recently completed the acquisition of ZuriMED, a developer of rotator cuff reinforcement technology, which enhances the company's shoulder repair offerings and expands its product portfolio in the orthopaedic segment.
  • The company reported strong third-quarter earnings on July 30, 2026, with actual earnings per share of $3.69, which exceeded the consensus estimate of $3.49, and revenue of $6.59 billion, surpassing the consensus estimate of $6.58 billion.
  • Stryker Co. maintains a consistent dividend policy, having recently declared a quarterly dividend of $0.88 per share, which represents an annualized yield of approximately 1.1% and a payout ratio of 36.48%, providing income stability for investors.
  • The stock currently trades at $303.85, which is below the consensus price target of $370.68 set by analysts, suggesting potential upside as the company continues to execute its growth strategy in medical technology.
  • Institutional investors have shown renewed interest in the stock, with firms like Verdence Capital Advisors LLC increasing their stake by 103.6% and Noesis Capital Management Corp raising its holdings by 36.3% during the third quarter, indicating confidence in the company's long-term prospects.

Stryker
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Stryker Co. for these reasons:

  • Insider selling has been significant recently, with Director Ronda E. Stryker selling 300,000 shares in August 2026 and other insiders selling a total of 351,267 shares worth approximately $118.2 million over the last ninety days, which may signal a lack of confidence from company leadership.
  • The stock has experienced a decline from its 52-week high of $389.33 to the current price of $303.85, reflecting a drop of over 22% and indicating potential market concerns about the company's valuation or operational performance.
  • Analysts have recently lowered their price targets for Stryker Co., with JPMorgan Chase & Co. reducing its target from $400.00 to $350.00 and Royal Bank of Canada decreasing its target from $435.00 to $420.00, suggesting a more cautious outlook on the stock's near-term performance.
  • The company's P/E ratio of 31.49 is relatively high compared to the broader market, which may indicate that the stock is overvalued relative to its earnings, particularly if growth slows or margins face pressure from supply constraints and operational headwinds.
  • Short interest in Stryker Co. has increased in recent months, with shares shorted rising to 5.7 million as of October 15, 2026, from 4.4 million in April 2026, suggesting that some investors are betting against the stock's future performance.

SYK Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Stryker is $369.00, with a high forecast of $465.00 and a low forecast of $298.00.

24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last year. There are currently 6 hold ratings, 17 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SYK shares.

According to analysts, Stryker's stock has a predicted upside of 19.67% based on their 12-month stock forecasts.

Over the previous 90 days, Stryker's stock had 1 upgrade and 1 downgrade by analysts.

Analysts like Stryker more than other "healthcare" companies. The consensus rating for Stryker is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how SYK compares to other companies.


MarketBeat monitors more than a dozen sources for Stryker analyst ratings, with the most recent rating issued on 10/12/2026.
From Our Partners